Search for: "PFIZER V TEVA PHARMACEUTICALS" Results 1 - 20 of 183
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
1 May 2024, 1:18 pm by Melissa Tremblay
Teva Pharmaceuticals, an AKS-based FCA case involving speaker programs sponsored by drug manufacturers, the U.S. [read post]
5 Apr 2023, 5:18 am by Annsley Merelle Ward
A similar situation arose a few years in Pfizer v Roche [2019] EWHC 1520 (Pat). [read post]
14 Feb 2023, 12:29 pm
</span> </p> <p> <span style="display: initial;"> <br/> </span> </p> <p> <span style="display: initial;"> <span style="display: initial;"> Some well-known patent infringement </span> </span> <a href="https://www.greyb.com/largest-patent-infringement-awards/" target="_blank"… [read post]
17 Mar 2020, 1:32 pm by Noble McIntyre
One Lot of Topotecan Injection 4 mg/4 mL (1 mg/mL) has been recalled by Teva Pharmaceuticals due to the presence of particulate matter. [read post]
3 Mar 2020, 4:00 am by Alan Macek
In Novartis Pharmaceuticals Canada Inc. v. [read post]
18 Feb 2020, 4:00 am by Martin Kratz
Pfizer Canada ULC, 2020 FC 1, at para. 56. [15] See Seedlings Life Science Ventures, LLC v. [read post]
14 May 2019, 11:24 am by Lawrence B. Ebert
Cir. 2009) (quoting Pfizer, Inc. v. [read post]
4 Dec 2018, 10:34 am by Sanford Hausler
  It sought to obtain settlement agreement, licensing agreements and any other related agreements between King Pharmaceuticals , Meridian Technologies, Inc. and Pfizer, Inc., the respondents in the proceeding (collectively, the "Respondents") and Teva Pharmaceutical Industries, Ltd. [read post]
22 Mar 2016, 4:00 am by Paula Bremner
Although manufacturers are still fragmented, consolidations continue based on “better rationales” (given the standard merger rewards may not necessarily exist): including Pfizer/Hospira, Teva/Actavis and focused start-ups. [read post]
6 Nov 2015, 6:58 am
 The patent belongs Warner-Lambert, a company that was acquired by Pfizer in 2000. [read post]
14 May 2015, 4:00 am by Paula Bremner
In Apotex v Pfizer Canada, 2014 FCA 250 [celecoxib NOC case], The Court of Appeal was focussed on interpreting the Promise in favour of Pfizer. [read post]